(Q38703518)

5 September 2017

title

Patient-reported outcomes in the evaluation of toxicity of anticancer treatments (English)

1 reference

5 September 2017

2

Ethan Basch

1 reference

5 September 2017

Massimo Di Maio

1

1 reference

5 September 2017

Jane Bryce

series ordinal

3

1 reference

5 September 2017

Francesco Perrone

series ordinal

4

1 reference

5 September 2017

language of work or name

English

0 references

publication date

20 January 2016

1 reference

Nature Reviews Clinical Oncology

5 September 2017

published in

1 reference

5 September 2017

volume

13

1 reference

5 September 2017

issue

5

1 reference

5 September 2017

page(s)

319-325

1 reference

Reliability of adverse symptom event reporting by clinicians

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.222

The missing voice of patients in drug-safety reporting

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.222

Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.222

Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.222

Patient-reported outcomes and the evolution of adverse event reporting in oncology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.222

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.222

Patient adherence and persistence with oral anticancer treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.222

COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.222

Correlation of patient and caregiver ratings of cancer pain.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.222

Assessing health-related quality of life in palliative care: comparing patient and physician assessments.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.222

How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.222

Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.222

Clinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient's self-reported questionnaire.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.222

Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.222

Adding the patient perspective to comparative effectiveness research

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.222

Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.222

Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.222

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.222

Optimal recall periods for patient-reported outcomes: challenges and potential solutions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.222

Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.222

Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.222

Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.222

Use of patient-reported outcomes to improve the predictive accuracy of clinician-reported adverse events.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.222

PROceeding With the Patient-Reported Outcomes (PROs) Version of the Common Terminology Criteria for Adverse Events

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.222

Tolerability of hormone therapies for breast cancer: how informative are documented symptom profiles in medical notes for 'well-tolerated' treatments?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.222

Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.222

Self-evaluation of Adjuvant Chemotherapy-Related Adverse Effects by Patients With Breast Cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.222

Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database.

31 March 2020

1 reference

12 December 2020

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

1 reference

12 December 2020

Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition

1 reference

12 December 2020

Italian multicenter survey to evaluate the opinion of patients and their reference clinicians on the "tolerance" to targeted therapies already available for non-small cell lung cancer treatment in daily clinical practice

1 reference

12 December 2020

Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance

1 reference

12 December 2020

10.1038/NRCLINONC.2015.222

Identifiers

DOI

1 reference

5 September 2017

1 reference